Find in Library

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

oleh: D.S. Siegel, K. Weisel, A. Zahlten-Kumeli, R. Medhekar, S. Sapra, B. Ding, X. Leleu